title: 90Y-DOTATOC as a Therapeutic Option for Complex Recurrent or Progressive Meningiomas.
abstract: The standard treatment of meningiomas is surgery or radiotherapy. Complex, especially recurrent or progressive cases, may exhibit tumor growth involving critical neurovascular structures or diffuse growth, resulting in limited efficacy and higher risk of standard treatment. We evaluated whether somatostatin receptor-targeted radionuclide therapy with (90)Y-DOTATOC may be a therapeutic option.
  
  
  METHODS
  Fifteen patients with recurrent or progressive meningiomas after multimodal pretreatment or unfavorable medical risk profile were treated with systemic (90)Y-DOTATOC. Endpoints were progression-free survival and toxicity.
  
  
  RESULTS
  Usually applied doses were 7,400 MBq/m(2) of (90)Y-DOTATOC in 2 fractions. Mean observation time was 49.7 mo (range, 12-137 mo). Overall median progression-free survival was at least 24 mo. Toxicity was moderate, mostly hematologic (n = 8) and transient.
  
  
  CONCLUSIONS
  (90)Y-DOTATOC therapy is feasible and may represent a promising second- or third-line option for complex meningiomas, which are progressive or otherwise not treatable with a reasonable risk-benefit ratio.
authors: University Children's Hospital, Zürich, Switzerland.
authors: Karine
authors: K
authors: Gerster-Gilliéron
authors: Nuclear Medicine, Cantonal Hospital, St. Gallen, Switzerland.
authors: Flavio
authors: F
authors: Forrer
authors: Nuclear Medicine, University Hospital, Freiburg, Germany.
authors: Helmut
authors: H
authors: Maecke
authors: Nuclear Medicine, University Hospital, Basel, Switzerland.
authors: Jan
authors: J
authors: Mueller-Brand
authors: Neurosurgery Practice, Bern, Switzerland; and.
authors: Adrian
authors: A
authors: Merlo
authors: Neurosurgery, University Hospital, Basel, Switzerland Dominik.Cordier@usb.ch.
authors: Dominik
authors: D
authors: Cordier
mesh_terms: D000328:Adult; D000368:Aged; D018572:Disease-Free Survival; D004307:Dose-Response Relationship, Radiation; D023381:Endpoint Determination; D005260:Female; D006801:Humans; D007668:Kidney / Q000528:radiation effects; D008279:Magnetic Resonance Imaging; D008297:Male; D008579:Meningioma / Q000532:radiotherapy*; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D015282:Octreotide / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019275:Radiopharmaceuticals / Q000009:adverse effects / Q000627:therapeutic use*; D017481:Receptors, Somatostatin / Q000187:drug effects / Q000378:metabolism; D016896:Treatment Outcome
chemical_list: D019275:Radiopharmaceuticals; D017481:Receptors, Somatostatin; C496730:90Y-octreotide, DOTA-Tyr(3)-; D015282:Octreotide
keywords: 90Y; DOTATOC; meningioma; peptide receptor radionuclide therapy; somatostatin-receptor